Gram-negative bacteria-producing extended-spectrum β-lactamases (ESBLs) are found
to be truly multiresistant pathogens causing severe clinical problems. In our investigations,
fifteen class C β-lactamases with extended substrate spectra have been reported in
Gram-negative pathogens. Because of the emergence and dissemination of these enzymes,
we propose that these enzymes be recognized as class C ESBLs (cESBLs), although most
of the known ESBLs are class A and D β-lactamases. To decrease the selective pressure
of antimicrobial drugs and minimize antimicrobial resistance, it is necessary for
health-care professionals to recognize the presence of emerging cESBLs as a new and
disturbing trend in antimicrobial resistance of Gram-negative pathogens. Because there
is currently no drug development against cESBL-producing Gram-negative pathogens in
progress and large pharmaceutical companies have largely withdrawn from research and
development of new antimicrobial drugs, there is a tremendous need for the development
of new β-lactams (or β-lactamase inhibitors) by focused cooperation between academia
and small pharmaceutical companies, using the similar structural mechanism (a potential
therapeutic target) of the extended substrate spectrum shown in most cESBLs.
The consensus view about antimicrobial resistance is that severe clinical problems
arise from the emergence of antibiotic resistance in Gram-negative pathogens causing
nosocomial infections, and from the lack of new antimicrobial agents to challenge
the threat [1]. There are four disturbing trends (extending substrate spectra) in
the increasing antimicrobial resistance of Gram-negative pathogens [1]: (i) class
B β-lactamases (metallo-β-lactamases) conferring resistance to almost all β-lactam
antibiotics [2]; (ii) a bifunctional aminoglycoside-modifying enzyme [3]; (iii) the
evolution of a fluoroquinolone-modifying enzyme from an aminoglycoside acetyltransferase
[4]; and (iv) a new plasmid-borne fluoroquinolone efflux determinant [5]. These disturbing
trends indicate that options for the treatment of health-care–associated Gram-negative
infections are perilously limited as the organisms expand their ability to evade existing
antimicrobial agents [1],[6]. Here we wish to draw attention to a new disturbing trend
(the recently emerging class C extended-spectrum β-lactamases [ESBLs]), and to the
antimicrobial drug development for class C ESBLs. We suggest also that the category
of ESBLs has to be expanded.
Epidemiology and Characteristics of Class C ESBLs
Generally, ESBLs are defined as β-lactamases able to hydrolyze the penicillins, cephalosporins
(first-, second-, and third-generation), and monobactams (aztreonam), but not the
cephamycins or carbapenems [7]. In other words, ESBLs have an extended substrate spectrum
as compared with their parent types (non-ESBLs). ESBLs can also be inhibited by β-lactamase
inhibitors such as clavulanic acid. Most of the known ESBLs are class A and D β-lactamases
[7], but 15 class C β-lactamases with extended substrate spectra have been reported
in Gram-negative pathogens isolated from clinical specimens of patients since the
first description of GC1 in 1995 (Table 1). Because of the emergence and dissemination
of these enzymes, we propose that these enzymes are recognized as class C ESBLs. Then
class A, C, and D ESBLs would be designated aESBLs, cESBLs, and dESBLs, respectively.
10.1371/journal.ppat.1000221.t001
Table 1
Epidemiology and characteristics of class C extended-spectrum β-lactamases (cESBLs)
Enzyme*
Extended Substrate Spectrum† (Parent Enzyme)
Country of Origin (Clinical Isolation)
Bacterial Species
Region (Mutation Site)‡ Causing Extended Substrate Spectrum
Reference
GC1
CAZ, ATM (P99)
Japan, 1992
E. cloacae GC1
Ω-loop (the insertion of Ala-Val-Arg after position 210)
[8],[10]
SRT-1
CAZ, CTX, CMX (SST-1)
Japan, 1985
S. marcescens GN16694
Ω-loop (Glu213 → Lys)
[28]
SMSA (SerR)
CAZ, FEP, FPI (SLS73, SerS)
France, 2000
S. marcescens SMSA
Ω-loop (Ser220 → Tyr)
[29]
CHE
CTX, FEP, FPI (P99)
France, 1998
E. cloacae CHE
R2-loop (a six-amino-acid-deletion, SKVALA at positions 289–294)
[11]
Ear2
CTX, FEP (Ear1)
France, 2001
E. aerogenes Ear2
R2-loop (Leu293 → Pro)
[30]
AmpCD
CAZ, FEP, FPI, inhibitor-sensitive (AmpCR, revertant)
Japan, 1994
E. coli HKY28
R2-loop (a tripeptide deletion, GSD, at positions 286–288)
[31]
HD
CAZ, FEP, FPI (S3)
France, 2001
S. marcescens HD
R2-loop (a four-amino-acid-deletion, MNGT, at positions 293–296)
[16]
EC14
CAZ, FEP (EC1)
France, 2002–2005
E. coli EC14
R2-loop (Val298 → Leu)
[17]
EC15
CAZ, FEP (EC1)
France, 2002–2005
E. coli EC15
R2-loop (His296 → Pro)
[17]
EC17
CAZ, FEP (EC1)
France, 2002–2005
E. coli EC17
R2-loop (His296 → Pro)
[17]
EC19
CAZ, FEP (EC1)
France, 2002–2005
E. coli EC19
R2-loop (His296 → Pro)
[17]
CMY-19
CAZ, FEP, FPI (CMY-9)
Japan, 1996
K. pneuminiae HKY327
R2-loop (Ile292 → Ser)
[32]
CMY-10
CAZ, IMP (P99)
Korea, 1999
E. aerogenes K9911729
R2-loop (a tripeptide deletion, PPA, at positions 303–305)
[24]
BER
CAZ, CTX, CRO, FEP, IMP (EC2)
France, 2006
E. coli BER
R2-loop (the insertion of Ala-Ala after position 293)
[18]
MHN-7.6
CAZ, FEP, FPI (MHN)
In vitro mutation
E. coli K12 strain MI1443
R2-loop (Val298 → Glu)
[9]
AmpC1
CAZ, FEP (P99)
In vitro mutation
E. coli JM83
R2-loop (Leu293 → Pro)
[33]
Seven mutant enzymes
CAZ, FEP (CMY-2)
In vitro mutation
E. coli DH5αE
R2-loop (Val291 → Ala[Gly]; Ala292 → Pro; Leu293 → Pro; Ala294 → Glu; Leu296 → Pro;
Ala298 → Val)
[34]
520R
CAZ, FPI (S3)
In vitro mutation
E. coli DH5α
H-2 helix (Thr64 → Ile)
[35]
KL
CAZ, FEP, FPI (S4)
France, 2001
E. coli KL
H-11 helix (Val350 → Phe)
[19]
*
Crystallographic structures from distinct GC1 (Protein Data Bank [PDB] code 1GCE)
and CMY-10 (PDB code 1ZKJ) only have been resolved. SerR is the in vitro site-directed
mutant of SLS73 (SerS). All enzymes except plasmid-encoded CMY-10 and CMY-19 are chromosomal
cESBLs. All enzymes except several enzymes (SerR, SerS, AmpCR, AmpC1 [in vitro Leu-293-Pro
mutant of P99], seven mutants of CMY-2, MHN-7.6, and 520R) are the naturally (clinically)
occurring cESBLs produced by clinical isolates. AmpCD is the only inhibitor-(tazobactam
and sulbactam)sensitive cESBL.
†
CAZ, ceftazidime; CTX, cefotaxime; CMX, cefmenoxime; CRO, ceftriaxone; FEP, cefepime;
FPI, cefpirome; IMP, imipenem; ATM, aztreonam. Each cESBL has extended its substrate
specificity in comparison with each parent enzyme (non-cESBL).
‡
Ω-loop lays from residues 189 to 226 in P99 β-lactamase. R2-loop lays from residues
289 to 307 in CMY-10 β-lactamase. The position of the N-terminal amino acid of the
mature enzyme (without the respective signal peptide) is designated as position 1
of the amino acid sequence. The tripeptide deletion of AmpCD is located just before
the R2-loop but causes a structural change in the R2-loop. Glu213 → Lys, the substitution
of glutamic acid (Glu) by lysine (Lys) at residue 213.
The cESBLs were first defined as follows: i) extended specificity class C β-lactamase
for GC1 in 1995 [8]; ii) extended-spectrum AmpC-type β-lactamase for MHN-7.6 in 1998
[9]; iii) extended-spectrum class C β-lactamase for GC1 in 1999 [10]; and iv) extended-spectrum
AmpC β-lactamase (ESAC) for CHE in 2001 [11]. Class C β-lactamase was designated AmpC
β-lactamase [12]. Therefore, extended-spectrum class C (AmpC) β-lactamase can be designated
class C extended-spectrum β-lactamase (cESBL). Most cESBL (13 of 15 natural cESBLs
produced by Gram-negative pathogens isolated from clinical specimens of patients:
SMSA, CHE, Ear2, AmpCD, HD, EC14, EC15, EC17, EC19, CMY-19, BER, 520R, and KL) have
extended their substrate specificity to third- and fourth-generation cephalosporins
(Table 1). Some cESBLs (CMY-10 and BER) can hydrolyse carbapenems (imipenem or meropenem),
which have the same substrate specificity as that of aESBLs such as GES-5 [13]. A
cESBL (AmpCD) can be inhibited also by β-lactamase inhibitors (tazobactam and sulbactam)
just like aESBLs and dESBLs. The hydrolytic efficiency (k
cat/K
m) of cESBLs for ceftazidime and cefotaxime was higher than or similar to that of
SHV-38 [14] and CTX-M-15 [15], typical aESBLs. Some β-lactamase investigators [16]–[19]
have tried to distinguish the difference between ESACs and cESBLs, but, except for
cephamycins (cefoxitin and cefotetan), hydrolysis patterns do not differ between ESACs
and cESBLs. Furthermore, ESBL-producing clinical isolates were also resistant to cephamycins
by reduced outer membrane permeability [20]. In 2003, Hanson warned that if we have
failed to distinguish between ESBL and plasmid-encoded class C β-lactamase (non-cESBL)
producers, we would run the risk of the emergence of cESBLs [21]. Unfortunately, cESBLs
have already emerged, and the phenotypic susceptibility testing to distinguish between
aESBLs (or dESBLs) and emerging cESBLs is very difficult.
Treatment for cESBL-Producing Gram-Negative Pathogens
The Infectious Diseases Society of America identified six top-priority dangerous pathogens
(e.g., ESBL-producing Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa,
vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus,
and Aspergillus species) for which there are few or no drugs in late-stage development,
further limiting the choice of an appropriate and safe treatment for these infections
[22],[23]. Three of six dangerous pathogens are antibiotic-resistant Gram-negative
bacteria. Recently, antimicrobial drugs against ESBL-producing Gram-negative pathogens
accounted for about 15% (2 of 13) of all antimicrobial drugs undergoing development
in phase II or later clinical studies [22]. There are no drug developments against
cESBL-producing Gram-negative pathogens.
Rubinstein and Zhanel, hospital physicians, have stated that physicians are increasingly
forced to use the carbapenems and fluoroquinolones (ciprofloxacin or levofloxacin)
as first-line therapy for ESBL-producing Gram-negative pathogens, but the situation
will become even more severe as ESBL-producing organisms increasingly become concomitantly
resistant to the fluoroquinolones [6]. However, we recently found that the CMY-10
cESBL had higher imipenem-hydrolysing activity than OXA-23, a class D carbapenemase
[24]. Because this extended substrate spectrum of cESBLs can threaten the management
of infections by Gram-negative pathogens producing these enzymes, new antimicrobial
drugs against cESBL-producing Gram-negative pathogens are urgently needed. To develop
these antimicrobial drugs, it is necessary to know the operative mechanism of cESBLs
to extend their substrate spectrum.
Antimicrobial Drug Development for cESBLs
How do the cESBLs extend the substrate spectrum? The crystallographic structures can
answer this question. Until now, there are two only resolved crystallographic structures
of cESBLs: (i) GC1 (Protein Data Bank [PDB] code, 1GCE) [10]; and (ii) CMY-10 (PDB
code, 1ZKJ) [24]. Kinetic data and the crystal structure of GC1 showed that GC1 was
a natural (clinically isolated) cESBL due to the flexibility of the Ω-loop caused
by the insertion of Ala-Val-Arg after position 210 [8],[10]. As shown in the Table
1, this structural characteristic of chromosomal GC1 provides insights into the molecular
basis of extended substrate spectrum shown in only three cESBLs (GC1, SRT-1, and SMSA).
But our kinetic data and crystal structure [24] of a plasmid-encoded cESBL (i.e.,
CMY-10) reveal the operative molecular strategy of most cESBLs (73%, 11 of the total
15) to extend their substrate spectrum. The region responsible for the extended substrate
spectrum is the R2-loop (amino acid residues 289–307; Figure 1) [24]. Our sequence
alignment of natural (clinically isolated) cESBLs shows that the R2-loop includes
all regions responsible for the extended substrate spectrum in most (11 of the total
15) cESBLs: Ω-loop in three cESBLs; H-2 helix in a 520R cESBL (not natural); H-11
helix in a KL cESBL (Table 1 and Figure 1). These natural (from clinical isolates)
mutations in the R2-loop can change the architecture of the active site in cESBLs,
thereby affecting their hydrolysing activity. Owing to a three-amino-acid deletion
(amino acid residues 303–305) in CMY-10, for example, the R2-loop in the R2 active
site (i.e., the region that accommodates the R2 side-chain at C3 of the β-lactam nucleus
in oxyimino-cephalosporins) displays noticeable structural alterations: the significant
widening of the R2 active site. Therefore, the bulky R2 side-chain of oxyimino-cephalosporins
could fit snugly into the significant widening of the R2 active site in this way.
In view of no drug developments against cESBL-producing Gram-negative pathogens, new
β-lactams or β-lactamase inhibitors need to be developed by the structure-based drug
design (SBDD) method [25] using a similar mechanism (the significant widening of the
R2 active site) of the extended substrate spectrum shown in most cESBLs. Clinically
available β-lactamase inhibitors co-administered with less effective β-lactams are
effective against class A β-lactamases, but show little or no activity against class
C β-lactamases. Therefore, class C β-lactamases are an excellent drug target with
accurate structural information [25]. Since Gram-negative pathogens producing cESBLs
are increasing in emergence and spreading among organisms causing nosocomial infections
(Table 1), there is an urgent need to develop an inhibitor of cESBLs or to discover
new antimicrobial drugs for these cESBL-producing clinical isolates. Although large
pharmaceutical companies have largely withdrawn from research and development of new
antimicrobial drugs, a few academic research groups (e.g., our group, or Shoichet's
laboratory [26]) and small pharmaceutical companies (e.g., Novexel [27], which has
been spun out of Aventis and Anacor that has formed a worldwide strategic alliance
with GlaxoSmithKline) are seeking these new β-lactamase inhibitors. The discovery
of some lead compounds against CMY-10 β-lactamases by SBDD is in progress, by focused
cooperation between academia and small pharmaceutical companies.
10.1371/journal.ppat.1000221.g001
Figure 1
Ribbon diagram of crystallographic structure of CMY-10 (a cESBL).
The image was rendered with PyMOL, available on the Internet (http://sourceforge.net/projects/pymol).
The R2-loop is represented as red, while the Ω-loop, H-2 helix, and H-11 helix are
depicted in violet, blue, and cyan, respectively. The R1 active site (central upper
region) is surrounded by the Ω-loop and the R2 active site (central lower region)
by the R2-loop and H-11 helix. The nucleophile (Ser65), attacking the carbonyl carbon
of β-lactam ring, is present in the H-2 helix.
Conclusion
Since the emergence and dissemination of fifteen class C extended-spectrum β-lactamases
(ESBLs) produced by Gram-negative pathogens isolated from clinical specimens of patients,
the category of ESBLs has broadened to include class C β-lactamases with extended
substrate spectrum. We propose that these enzymes be recognized as class C ESBLs (cESBLs).
Phenotypic susceptibility testing to distinguish the difference between organisms
producing general ESBLs (e.g., aESBLs or dESBLs) or emerging cESBLs is very challenging.
The difficulty in type identification of ESBLs hinders hospital infection control
and the ability of the physician to prescribe the most appropriate antibiotic, thus
increasing the selective pressure and generating antibiotic resistance. It is necessary
for health-care professionals to recognize the presence of emerging cESBLs as a new
and disturbing trend in antimicrobial resistance of Gram-negative pathogens. Furthermore,
there is currently no drug development in progress against cESBL-producing Gram-negative
pathogens. Therefore, there is a tremendous need for the development of new β-lactams
or β-lactamase inhibitors by the structure-based drug-design method using the similar
structural mechanism (the significant widening of the R2 active site) of the extended
substrate spectrum shown in most cESBLs.
Accession Number
The Protein Data Bank (PDB, http://www.rcsb.org/pdb/) accession code for the protein
discussed in this paper is CMY-10 (1ZKJ, [24]).